Abstract
New data from the phase III LACEWING trial support the safety and feasibility of combining gilteritinib with azacitidine in patients with newly diagnosed FLT3‐mutated acute myeloid leukemia who are not eligible for induction therapy, suggesting an important new treatment approach for these patients.